NexImmune (NASDAQ:NEXI) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.
Profitability
This table compares NexImmune and Nurix Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
NexImmune | N/A | N/A | N/A |
Nurix Therapeutics | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of current ratings and target prices for NexImmune and Nurix Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
NexImmune | 0 | 0 | 3 | 0 | 3.00 |
Nurix Therapeutics | 0 | 0 | 6 | 0 | 3.00 |
NexImmune presently has a consensus target price of $33.3333, suggesting a potential upside of 78.54%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 64.44%. Given NexImmune's higher probable upside, equities analysts clearly believe NexImmune is more favorable than Nurix Therapeutics.
Earnings and Valuation
This table compares NexImmune and Nurix Therapeutics' gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
NexImmune | N/A | N/A | N/A | N/A | N/A |
Nurix Therapeutics | N/A | N/A | N/A | N/A | N/A |
Insider and Institutional Ownership
82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Nurix Therapeutics beats NexImmune on 2 of the 3 factors compared between the two stocks.